Oncology
Pancreas Cancer
3
Pipeline Programs↗
10
Active Trials↗
6
Companies Involved↗
Pancreas Cancer is an early-stage landscape with 3 programs across 6 companies. The most active players are Johnson & Johnson, Bristol-Myers Squibb, ImmunoMet Therapeutics, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 13
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
36
clinical trials
Terminated10 · 28%
Completed10 · 28%
Active, not recruiting6 · 17%
Recruiting4 · 11%
Unknown status3 · 8%
Withdrawn3 · 8%
Clinical Trials
Trial Activity
36 trials
Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
Active, not recruiting·—·Phase 4·NCT05634720·20 enrolled
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Active, not recruiting·—·Phase 2·NCT05604560·25 enrolled
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01088789·71 enrolled
Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Completed·—·Phase 2·NCT00417976·42 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)